Cargando…

PB2583: RUXOLITINIB IN SEVERE AND CRITICAL COVID19 REQUIRING CPAP

Detalles Bibliográficos
Autores principales:	Festuccia, Moreno Benedetto, Evangelista, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428763/ http://dx.doi.org/10.1097/01.HS9.0000977024.02738.3a

Ejemplares similares

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

PB2056: MYELOFIBROSIS IN PATIENTS OLDER THAN 70 YEARS: IS TREATMENT WITH RUXOLITINIB WORTH IT?
por: Montero, M. I.
Publicado: (2022)

PB2048: EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY
por: Chen, C., et al.
Publicado: (2022)

PB2457: RUXOLITINIB AS TREATMENT IN PATIENTS WITH ACUTE AND CRONIC GRAFT-VERSUS-HOST DISEASE. REAL WORLD EVIDENCE
por: José Jiménez Nájar, Francisco, et al.
Publicado: (2023)

PB2057: REAL -WORLD OVERALL SURVIVAL OF MYELOFIBROSIS PATIENTS ON RUXOLITINIB – A 6 YEAR ANALYSIS IN ALBANIAN POPULATION
por: Perolla, A., et al.
Publicado: (2022)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
por: Mascarenhas, John, et al.
Publicado: (2023)

PB2179: RETROSPECTIVE ANALYSIS OF THE EFFICACY AND SAFETY OF RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD). A SINGLE-INSTITUTION EXPERIENCE.
por: Muñiz, Ó., et al.
Publicado: (2022)

PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF
por: Kuykendall, Andrew, et al.
Publicado: (2023)

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIALS
por: Al-Ali, Haifa Kathrin, et al.
Publicado: (2023)

PB2564: COVID-19 AND FERRITIN
por: Kuiavovych, Bohdana, et al.
Publicado: (2023)

PB2253: NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AS A PREDICTOR OF SEVERE COVID-19 ON ADMISSION
por: Ababou, M., et al.
Publicado: (2022)

PB2452: PREVALENCE AND SEVERITY OF COVID-19 IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS IN CHINA
por: Gao, Hongye, et al.
Publicado: (2023)

PB2322: TTP AFTER COVID 19
por: Gagloeva, D., et al.
Publicado: (2022)

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Palandri, Francesca, et al.
Publicado: (2023)

PB2303: THROMBOCYTOPENIA IN COVID-19 PATIENTS ON ECMO SUPPORT
por: Jones, C., et al.
Publicado: (2022)

PB2280: COVID-19 INFECTION IN PATIENTS WITH ACUTE LEUKEMIA
por: Shapetska, M., et al.
Publicado: (2022)

PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY.
por: Catania, Federica, et al.
Publicado: (2023)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB2580: THE VALUE OF HEMATOLOGIC INFLAMMATION INDICES FOR COVID–19 PATIENTS
por: Petridou, Eleni, et al.
Publicado: (2023)

PB2666: MAIN DISORDERS AND COAGULATION PARAMETERS IN PATIENTS WITH COVID-19
por: Kubarova, Valentyna, et al.
Publicado: (2023)

PB2709: BURDEN OF SEVERE INFECTIONS IN PRIMARY IMMUNODEFICIENCY DISEASES
por: Aggarwal, Saurabh, et al.
Publicado: (2023)

PB1801: MYCN IS REQUIRED FOR MAINTAINING AN ONCOGENIC CHARACTERISTICS OF LEUKEMIA CELLS IN ACUTE MYELOID LEUKEMIA
por: Huang, Nanfang, et al.
Publicado: (2023)

PB2283: COVID-19 (SARS-COV-2 INFECTION) IN LYMPHOMA PATIENTS
por: Tytorenko, I., et al.
Publicado: (2022)

PB1908: COVID-19 INSIGHTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DIAGNOSIS AND TREATMENT
por: Musteata, V.
Publicado: (2022)

PB1870: COVID - 19 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: HOSPITAL MORALITY PREDICTORS
por: Kochneva, O., et al.
Publicado: (2022)

PB2282: HERPESVIRUSES REPLICATION DURING COVID-19 IN NON-HODGKIN’S LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

PB2572: LYMPHOPENIA RATE; A FREE EPIDEMIOLOGICAL BIOMARKER FOR COVID-19 PANDEMIC
por: Helali, Intissar, et al.
Publicado: (2023)

PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
por: Ranjit Kumar, C., et al.
Publicado: (2022)

PB2065: SEVERE HEMOLYSIS OF PNH PATIENTS ASSOCIATED WITH OMICRON INFECTION IN CHINA
por: Yang, Hui, et al.
Publicado: (2023)

PB2154: THE IMPACT OF DISEASE SEVERITY ON THE CLINICAL AND ECONOMIC BURDEN OF AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

PB2615: HOW WILL COVID-19 RELATED SYMPTOMS AND PLATELET COUNTS CHANGE IN ITP PATIENTS AFTER COVID-19 INFECTION?
por: Chen, Xiaoli, et al.
Publicado: (2023)

PB2259: MONOCYTE’S INVOLVEMENT IN INFLAMMATORY RESPONSE IN COVID-19 INFECTION IN CHRONIC RENAL DISEASE
por: Bumbea, V., et al.
Publicado: (2022)

PB2217: SICKLE CELL DISEASE IS A RISK FACTOR FOR THE PROGRESSION AND PROGNOSIS OF COVID-19
por: Goyal, V., et al.
Publicado: (2022)

PB2281: HOW TO AVOID FALSE-NEGATIVE AND FALSE-POSITIVE COVID-19 PCR TESTING
por: Fevraleva, I., et al.
Publicado: (2022)

PB2119: REDUCED OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS DURING THE COVID-19 PANDEMIC
por: Luchinin, Alexander, et al.
Publicado: (2023)

PB1935: MANAGEMENT OF NON-SEVERE APLASTIC ANEMIA: LABORATORY WORKUP AND TREATMENT PATTERNS.
por: Cassanello, G., et al.
Publicado: (2022)

PB2267: COVID-19 OUTCOMES ON HAEMATOLOGY PATIENTS WHO RECEIVED RITUXIMAB: SINGLE CENTRE STUDY
por: Hariharan, L., et al.
Publicado: (2022)

PB2671: AN INVESTIGATION INTO THE PREFERENCES OF PATIENTS REGARDING THE USE OF TELEMEDICINE STEMMING FROM THE COVID-19 PANDEMIC.
por: Kalloger, Steve, et al.
Publicado: (2023)

PB2705: PROFESSIONAL BURNOUT AMONG HEMATOLOGISTS AFTER THE OUTBREAK OF THE COVID-19 PANDEMIC AND ASSOCIATED FACTORS
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bplhjjp208fq8j8ag9rkl4tck9